GSK cancer drug wins EU orphan status for small-cell lung cancer
GSK PLC (LSE:GSK, NYSE:GSK) has secured Orphan Drug Designation in the European Union for GSK5764227, also known as GSK'227, a B7-H3-targeted antibody-drug conjugate being tested in small-cell lung cancer (SCLC). The decision is based on early clinical signals from the phase I ARTEMIS-001 study, where patients with extensive-stage SCLC who had relapsed after prior therapy showed durable responses.
Here's Why GSK (GSK) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
GSK: Compelling Value, No Red Flags Ahead Of Earnings, Blenrep FDA Decision Soon
GSK plc aka GlaxoSmithKline is rated a Buy at or below $45 due to relative undervaluation and a balanced, diversified portfolio. GSK's recent CEO transition and solid Q2 earnings have improved market sentiment, with growth led by Specialty Medicines and geographic expansion in Europe. Unlike peers, GSK faces limited Loss of Exclusivity risk, supporting steady revenue projections and justifying higher valuation multiples.
GSK's Hidden Growth Engines Beyond HIV And Oncology
GSK continues to successfully develop its oncology franchise. So, sales of its "gem" in the treatment of myelofibrosis, called Ojjaara, reached $183 million in the second quarter of 2025, increasing by 71% year-on-year. In addition, GSK increased its 2025 sales growth outlook from a "low-double digit percentage" to a "low-teens percentage."
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Will Glaxo (GSK) Beat Estimates Again in Its Next Earnings Report?
Glaxo (GSK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
GSK chief exec Emma Walmsley to leave in January
GSK PLC (LSE:GSK, NYSE:GSK) chief executive Dame Emma Walmsley will step down from 1 January next year after almost nine years in the role. The pharmaceutical group has promoted its chief commercial officer, Luke Miels, as CEO designate.
GSK names Luke Miels as CEO designate
British drugmaker GSK said on Monday it has appointed Luke Miels as CEO designate and he will assume full responsibilities as chief executive on January 1, 2026.
GSK to Invest $30B in U.S. R&D and Manufacturing Over 5 Years
GSK commits $30B to U.S. R&D and manufacturing, with advanced AI-driven biopharma facilities set to expand jobs and innovation.
GSK commits $30bn to US drug research and manufacturing
GSK PLC (LSE:GSK, NYSE:GSK) will pour $30 billion into research, development and manufacturing in the United States over the next five years, in one of the largest overseas investment programmes announced by a UK-listed company. The commitment includes a fresh $1.2 billion package unveiled today to expand production capacity and adopt artificial intelligence and digital technologies across its American operations.
UK's GSK announces $30 billion U.S. pharma investment amid Trump state visit
British pharmaceutical giant GSK committed to investing at least $30 billion in U.S. research and developing and manufacturing over the next five years.
GSK and Eli Lilly are the latest multinational drugmakers to unveil plans to build more U.S. manufacturing plants and other operations, moves aimed partly at mitigating the threat of tariffs
GSK and Eli Lilly are the latest to unveil plans to add to manufacturing and increase other operations in America.
